Thanks wild, it really does sound like Leo is in a tough spot with the balancing act of keeping shareholders updated and respecting DF's wishes with regards to trial info communication. We can't lose sight that activating the "guardian angel of the human genome" is something big pharma has been trying to do for decades, so an announcement of this magnitude should be carefully managed and shared only after all comprehensive data analysis and review is complete.

What that means for us is simply that patience will be rewarded. 110mg/m2 dosing could be happening as we speak, we all know what signs we saw at 20/30mg, imagine what they are seeing now at 110!